Skip to content

A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes

A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03165786
Acronym
FREE
Enrollment
10
Registered
2017-05-24
Start date
2016-10-26
Completion date
2018-01-16
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type1diabetes

Keywords

fear of hypoglycemia, self-management, glycemic control, glycemic variability

Brief summary

This study is being conducted to determine the feasibility of a cognitive behavioral therapy intervention to reduce fear of hypoglycemia and improve glucose levels in young adults with type 1 diabetes.

Detailed description

In persons with type 1 diabetes (T1DM), iatrogenic hypoglycemia is the major limiting factor in achieving optimal blood glucose control. All persons with T1DM are at risk for hypoglycemia (blood glucose level \< 70 mg/dl), which is life-threatening and has serious physical symptoms and psychological sequelae that lead to profound fear of future hypoglycemic events. This fear results in greater glucose variability (the intra-day fluctuations in blood glucose), due to under- or overcompensation of food intake, insulin dosing, or physical activity, as well as anxiety, depression, and reduced quality of life. Greater glycemic variability (GV) is associated with a higher risk of hypoglycemia and diabetes complications. Young adults are particularly at risk because they report greater FOH and have poorer glycemic control. A major gap exists in how to manage FOH as a crucial component of diabetes self-care. Our overall objective is to reduce FOH and improve diabetes self-management, glycemic control, and variability in young adults with T1DM. We specifically aim to: (1) Determine the feasibility of an 8-week CBT-based intervention to reduce FOH and (2) obtain means and standard deviations of group differences from baseline to program completion on the outcomes of FOH, self-management, glycemic control and glycemic variability in young adults with T1DM who experience FOH. To achieve these aims, we propose a randomized control pilot trial in 10 young adults aged 18 to 30 years with T1DM. Participants will be screened for FOH levels. Eligible subjects will be randomized to the intervention (Fear Reduction Efficacy Evaluation \[FREE\]) program or attention control group. A 1-week run-in phase is planned, with baseline measures of FOH and 24-hour real-time continuous glucose monitoring recordings (RT-CGM) to calculate GV for both groups. The intervention group will participate in eight weekly one-hour sessions using a cognitive behavioral therapy (CBT) and exposure treatment for specific fears. RT-CGM and a daily FOH diary will be used as feedback cues. The control group will wear a 24-hour RT-CGM device during the same 8-week period and return for weekly RT-CGM site changes by study staff. At completion, FOH will be measured, and RT-CGM recordings will be analyzed to determine within-group and between-group differences. The findings from this proposed study will serve as the foundation for a larger clinical trial to reduce FOH and improve self-management, glycemic control, and variability. Meeting these goals will have important clinical implications to reduce diabetes complications and improve quality of life in young adults with T1DM.

Interventions

BEHAVIORALFREE

Cognitive behavioral therapy with real-time continuous glucose monitoring.

Sponsors

University of Illinois at Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

* type 1 diabetes ≥ 1 year * receive medical care from an endocrinologist * use insulin pump therapy * have self-reported fear of hypoglycemia (FOH;screening questionnaire)

Exclusion criteria

* pregnant or breastfeeding * actively treated for a mental health condition * have a co-existing chronic illness or taking medications (excluding insulin) that may influence diabetes self-management or glycemic variability

Design outcomes

Primary

MeasureTime frameDescription
Hypoglycemia Fear Scale Score (HFS_2)12 weeksA reliable and valid psychological scale. It is a 5-point Likert scale \[0-4\], that is summed for a single total continuous scale score. Scores may range from 0-72. Higher numbers indicate greater fear of hypoglycemia.

Secondary

MeasureTime frameDescription
Diabetes Self-Management Questionnaire Scale Score (DSMQ)12 weeksA reliable and valid behavioral scale, provides total continuous scale score, ranging from 0-81, higher numbers indicate better self-management.
Glycemic Control, the Average Blood Glucose Over a 2-3 Month Period of Time.12 weeksHemoglobin A1c represents the average blood glucose over a 2-3 month period and is an index of glycemic control. The American Diabetes Association recommends a hemoglobin A1C below 7% for most people with diabetes. Higher percentages indicate higher average blood glucose levels.
Glycemic Variability8 weeksTwenty-four hour fluctuations in glucose measured by a continuous glucose monitor that provides interstitial glucose readings every 5 minutes. This is a continuous measure. A higher standard deviation reflects greater glycemic variability.

Countries

United States

Participant flow

Recruitment details

Subjects will be recruited through Chicago metropolitan area university medical centers, local diabetes websites, and organizations using flyers, e-announcements, and recruitment letters.

Participants by arm

ArmCount
FREE Group
Cognitive behavioral therapy intervention with real-time continuous glucose monitoring. FREE: Cognitive behavioral therapy with real-time continuous glucose monitoring.
5
Control Group
Real-time continuous glucose monitoring
5
Total10

Baseline characteristics

CharacteristicFREE GroupTotalControl Group
A1C7.2 percentage
STANDARD_DEVIATION 1.29
7.58 percentage
STANDARD_DEVIATION 1.28
7.96 percentage
STANDARD_DEVIATION 1.3
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
5 Participants10 Participants5 Participants
Diabetes Self-management Questionnaire56.2 units on a scale
STANDARD_DEVIATION 13.2
54.2 units on a scale
STANDARD_DEVIATION 11.9
52.2 units on a scale
STANDARD_DEVIATION 11.5
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants10 Participants5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Glycemic variability66.04 mg/dL
STANDARD_DEVIATION 16.7
71.03 mg/dL
STANDARD_DEVIATION 15.9
79.3 mg/dL
STANDARD_DEVIATION 12.9
Hypoglycemia Fear Survey II - Worry subscale36.6 units on a scale
STANDARD_DEVIATION 18.4
37.7 units on a scale
STANDARD_DEVIATION 12.9
38.8 units on a scale
STANDARD_DEVIATION 6
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
5 Participants10 Participants5 Participants
Region of Enrollment
United States
5 participants10 participants5 participants
Sex: Female, Male
Female
2 Participants6 Participants4 Participants
Sex: Female, Male
Male
3 Participants4 Participants1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 50 / 5
other
Total, other adverse events
0 / 50 / 5
serious
Total, serious adverse events
0 / 50 / 5

Outcome results

Primary

Hypoglycemia Fear Scale Score (HFS_2)

A reliable and valid psychological scale. It is a 5-point Likert scale \[0-4\], that is summed for a single total continuous scale score. Scores may range from 0-72. Higher numbers indicate greater fear of hypoglycemia.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
FREE GroupHypoglycemia Fear Scale Score (HFS_2)21.4 units on a scaleStandard Deviation 10.9
Control GroupHypoglycemia Fear Scale Score (HFS_2)38.6 units on a scaleStandard Deviation 8.2
Secondary

Diabetes Self-Management Questionnaire Scale Score (DSMQ)

A reliable and valid behavioral scale, provides total continuous scale score, ranging from 0-81, higher numbers indicate better self-management.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
FREE GroupDiabetes Self-Management Questionnaire Scale Score (DSMQ)58.7 units on a scaleStandard Deviation 12.6
Control GroupDiabetes Self-Management Questionnaire Scale Score (DSMQ)50.6 units on a scaleStandard Deviation 12.1
Secondary

Glycemic Control, the Average Blood Glucose Over a 2-3 Month Period of Time.

Hemoglobin A1c represents the average blood glucose over a 2-3 month period and is an index of glycemic control. The American Diabetes Association recommends a hemoglobin A1C below 7% for most people with diabetes. Higher percentages indicate higher average blood glucose levels.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
FREE GroupGlycemic Control, the Average Blood Glucose Over a 2-3 Month Period of Time.6.94 percentageStandard Deviation 1.29
Control GroupGlycemic Control, the Average Blood Glucose Over a 2-3 Month Period of Time.7.66 percentageStandard Deviation 1.02
Secondary

Glycemic Variability

Twenty-four hour fluctuations in glucose measured by a continuous glucose monitor that provides interstitial glucose readings every 5 minutes. This is a continuous measure. A higher standard deviation reflects greater glycemic variability.

Time frame: 8 weeks

Population: Same as above

ArmMeasureValue (MEAN)Dispersion
FREE GroupGlycemic Variability73.0 mg/dLStandard Deviation 13.8
Control GroupGlycemic Variability73.3 mg/dLStandard Deviation 11.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026